Testosterone Replacement Therapy for Patients with Hypogonadism after High Dose-Rate Brachytherapy for High-Risk Prostate Cancer: A Report of Six Cases and Literature Review

• Main Authors: Suguru Kadomoto, Kazuyoshi Shigehara, Hiroaki Iwamoto, Hiroshi Yaegashi, Kouji Izumi, Yoshifumi Kadono, Atsushi Mizokami
• Format: Article
• Language: English
• Published: Korean Society for Sexual Medicine and Andrology 2020-01-01
• Series: The World Journal of Men's Health
• Subjects: hypogonadism; prostatic neoplasms; safety; testosterone

We had six cases of patients who were treated with long-term testosterone replacement therapy (TRT) after high dose-rate (HDR) brachytherapy and androgen deprivation therapy for high-risk prostate cancer. All patients were given testosterone enanthate by intramuscular injection every 3 to 4 weeks. Blood biochemistry including prostate specific antigen (PSA) level was evaluated every 3 to 6 months after TRT, and radiological imaging was performed every 12 months. All patients had slight increases in PSA within the normal range and not indicative of biochemical recurrence. A sudden increase in PSA was observed in one patient, but it finally decreased. Aging male symptoms scale and various metabolic factors were improved by TRT in all of cases. Although adverse events included polycythemia in one patient, no patients experienced disease recurrence or progression during TRT. Our results suggest TRT for high risk-patients with HDR brachytherapy for prostate cancer may be beneficial and safe.